Biology of Blood and Marrow Transplantation
Volume 13, Issue 5 , Pages 505-516 , May 2007

Allogeneic Stem Cell Transplantation for Aplastic Anemia

  • Philippe Armand

      Affiliations

    • Corresponding Author InformationCorrespondence and reprint requests: Philippe Armand, MD, PhD, Dana-Farber Cancer Institute, 44 Binney Street, Boston MA 02115.
    • ,
  • Joseph H. Antin

Received 31 January 2007 ,Accepted 12 February 2007.

References 

  1. Ehrlich P. Ueber einen Fall von Anämie mit Bemerkungen über regenerative Veränderungen des Knochenmarks. Charité-Annalen. 1888;13:300–309
  2. Shimamura A. Inherited bone marrow failure syndromes: molecular features. Hematol Am Soc Hematol Educ Program. 2006;63–71
  3. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006;108:2509–2519
  4. Young NS. Acquired aplastic anemia. Ann Intern Med. 2002;136:534–546
  5. Issaragrisil S, Kaufman DW, Anderson T, et al. The epidemiology of aplastic anemia in Thailand. Blood. 2006;107:1299–1307
  6. Bacigalupo A, Brand R, Oneto R, et al. Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy—the European Group for Blood and Marrow Transplantation experience. Semin Hematol. 2000;37:69–80
  7. Horowitz MM. Current status of allogeneic bone marrow transplantation in acquired aplastic anemia. Semin Hematol. 2000;37:30–42
  8. Margolis DA, Casper JT. Alternative-donor hematopoietic stem-cell transplantation for severe aplastic anemia. Semin Hematol. 2000;37:43–55
  9. Marsh J. Making therapeutic decisions in adults with aplastic anemia. Hematol Am Soc Hematol Educ Program. 2006;78–85
  10. Osgood EE, Riddle MC, Mathews TJ. Aplastic anemia treated with daily transfusions and intravenous marrow; case report. Am J Med. 1939;13:357–367
  11. Morrison M, Samwick AA. Intramedullary (sternal) transfusion of human bone marrow. JAMA. 1940;115:1708–1711
  12. Robins MM, Noyes WD. Aplastic anemia treated with bone-marrow infusion from identical twin. N Engl J Med. 1961;265:974–979
  13. Thomas ED, Storb R, Fefer A, et al. Aplastic anaemia treated by marrow transplantation. Lancet. 1972;1:284–289
  14. Camitta BM, Thomas ED, Nathan DG, et al. Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortality. Blood. 1976;48:63–70
  15. Territo MC. Autologous bone marrow repopulation following high dose cyclophosphamide and allogeneic marrow transplantation in aplastic anaemia. Br J Haematol. 1977;36:305–312
  16. Brodsky RA, Sensenbrenner LL, Smith BD, et al. Durable treatment-free remission after high-dose cyclophosphamide therapy for previously untreated severe aplastic anemia. Ann Intern Med. 2001;135:477–483
  17. Storb R, Longton G, Anasetti C, et al. Changing trends in marrow transplantation for aplastic anemia. Bone Marrow Transplant. 1992;10(Suppl 1):45–52
  18. McCann SR, Bacigalupo A, Gluckman E, et al. Graft rejection and second bone marrow transplants for acquired aplastic anaemia: a report from the Aplastic Anaemia Working Party of the European Bone Marrow Transplant Group. Bone Marrow Transplant. 1994;13:233–237
  19. Gale RP, Ho W, Feig S, et al. Prevention of graft rejection following bone marrow transplantation. Blood. 1981;57:9–12
  20. Champlin RE, Horowitz MM, van Bekkum DW, et al. Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results. Blood. 1989;73:606–613
  21. Gluckman E, Horowitz MM, Champlin RE, et al. Bone marrow transplantation for severe aplastic anemia: influence of conditioning and graft-versus-host disease prophylaxis regimens on outcome. Blood. 1992;79:269–275
  22. Deeg HJ, Socie G, Schoch G, et al. Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood. 1996;87:386–392
  23. Smith BR, Guinan EC, Parkman R, et al. Efficacy of a cyclophosphamide-procarbazine-antithymocyte serum regimen for prevention of graft rejection following bone marrow transplantation for transfused patients with aplastic anemia. Transplantation. 1985;39:671–673
  24. Storb R, Thomas ED, Weiden PL, et al. Aplastic anemia treated by allogeneic bone marrow transplantation: a report on 49 new cases from Seattle. Blood. 1976;48:817–841
  25. Storb R, Weiden PL, Sullivan KM, et al. Second marrow transplants in patients with aplastic anemia rejecting the first graft: use of a conditioning regimen including cyclophosphamide and antithymocyte globulin. Blood. 1987;70:116–121
  26. Storb R, Etzioni R, Anasetti C, et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood. 1994;84:941–949
  27. Kahl C, Leisenring W, Deeg HJ, et al. Cyclophosphamide and antithymocyte globulin as a conditioning regimen for allogeneic marrow transplantation in patients with aplastic anaemia: a long-term follow-up. Br J Haematol. 2005;130:747–751
  28. Ades L, Mary JY, Robin M, et al. Long-term outcome after bone marrow transplantation for severe aplastic anemia. Blood. 2004;103:2490–2497
  29. Wagner JL, Deeg HJ, Seidel K, et al. Bone marrow transplantation for severe aplastic anemia from genotypically HLA-nonidentical relatives (An update of the Seattle experience). Transplantation. 1996;61:54–61
  30. Kojima S, Matsuyama T, Kato S, et al. Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors: the Japan Marrow Donor Program. Blood. 2002;100:799–803
  31. Deeg HJ, O’Donnell M, Tolar J, et al. Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy. Blood. 2006;108:1485–1491
  32. Frickhofen N, Rosenfeld SJ. Immunosuppressive treatment of aplastic anemia with antithymocyte globulin and cyclosporine. Semin Hematol. 2000;37:56–68
  33. Maury S, Anderlini P, Viollier R, et al. Overcoming the negative impact of age using fludarabine-based conditioning regimens for HLA-identical sibling HSCT in patients with severe aplastic anemia (SAA): a study from the EBMT-SAA Working Party. Blood. 2006;108:3007
  34. Bacigalupo A, Locatelli F, Lanino E, et al. Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party. Bone Marrow Transplant. 2005;36:947–950
  35. Kang HJ, Shin HY, Choi HS, Ahn HS. Fludarabine, cyclophosphamide plus thymoglobulin conditioning regimen for unrelated bone marrow transplantation in severe aplastic anemia. Bone Marrow Transplant. 2004;34:939–943
  36. Resnick IB, Aker M, Shapira MY, et al. Allogeneic stem cell transplantation for severe acquired aplastic anaemia using a fludarabine-based preparative regimen. Br J Haematol. 2006;133:649–654
  37. Srinivasan R, Takahashi Y, McCoy JP, et al. Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation. Br J Haematol. 2006;133:305–314
  38. Kumar R, Prem S, Mahapatra M, et al. Fludarabine, cyclophosphamide and horse antithymocyte globulin conditioning regimen for allogeneic peripheral blood stem cell transplantation performed in non-HEPA filter rooms for multiply transfused patients with severe aplastic anemia. Bone Marrow Transplant. 2006;37:745–749
  39. Gomez-Almaguer D, Vela-Ojeda J, Jaime-Perez JC, et al. Allografting in patients with severe, refractory aplastic anemia using peripheral blood stem cells and a fludarabine-based conditioning regimen: the Mexican experience. Am J Hematol. 2006;81:157–161
  40. Gupta V, Ball SE, Yi QL, et al. Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia. Biol Blood Marrow Transplant. 2004;10:867–876
  41. Gupta V, Ball SE, Sage D, et al. Marrow transplants from matched unrelated donors for aplastic anaemia using alemtuzumab, fludarabine and cyclophosphamide based conditioning. Bone Marrow Transplant. 2005;35:467–471
  42. Rzepecki P, Sarosiek T, Szczylik C. Alemtuzumab, fludarabine and melphalan as a conditioning therapy in severe aplastic anemia and hypoplastic myelodysplastic syndrome—single center experience. Jpn J Clin Oncol. 2006;36:46–49
  43. Hows JM, Palmer S, Gordon-Smith EC. Use of cyclosporin A in allogeneic bone marrow transplantation for severe aplastic anemia. Transplantation. 1982;33:382–386
  44. Hows J, Palmer S, Gordon-Smith EC. Cyclosporine and graft failure following bone marrow transplantation for severe aplastic anaemia. Br J Haematol. 1985;60:611–617
  45. May WS, Sensenbrenner LL, Burns WH, et al. BMT for severe aplastic anemia using cyclosporine. Bone Marrow Transplant. 1993;11:459–464
  46. Stucki A, Leisenring W, Sandmaier BM, Sanders J, Anasetti C, Storb R. Decreased rejection and improved survival of first and second marrow transplants for severe aplastic anemia (a 26-year retrospective analysis). Blood. 1998;92:2742–2749
  47. Storb R, Deeg HJ, Farewell V, et al. Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Blood. 1986;68:119–125
  48. Locatelli F, Bruno B, Zecca M, et al. Cyclosporin A and short-term methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: results of a GITMO/EBMT randomized trial. Blood. 2000;96:1690–1697
  49. Deeg HJ, Seidel K, Casper J, et al. Marrow transplantation from unrelated donors for patients with severe aplastic anemia who have failed immunosuppressive therapy. Biol Blood Marrow Transplant. 1999;5:243–252
  50. Urban C, Benesch M, Sykora KW, Schwinger W, Lackner H. Non-radiotherapy conditioning with stem cell transplantation from alternative donors in children with refractory severe aplastic anemia. Bone Marrow Transplant. 2005;35:591–594
  51. Herrera-Garza J, Jaime-Perez J, Montemayor J, Ibarra-Peart R, Gomez-Almaguer D. High-dose peripheral blood stem cell transplant for multitransfused severe aplastic anaemia patients without antithymocyte globulin in the conditioning regimen. Bone Marrow Transplant. 1999;24:845–848
  52. Schwinger W, Urban C, Lackner H, et al. Unrelated peripheral blood stem cell transplantation with “megadoses” of purified CD34+ cells in three children with refractory severe aplastic anemia. Bone Marrow Transplant. 2000;25:513–517
  53. Schrezenmeier H, Bredeson C, Bruno B, et al. Comparison of allogeneic bone marrow and peripheral blood stem cell transplantation for aplastic anemia: collaborative study of European Blood and Marrow Transplant Group (EBMT) and International Bone Marrow Transplant Registry (IBMTR). Blood. 2003;102:267a
  54. Storb R, Prentice RL, Sullivan KM, et al. Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. Ann Intern Med. 1983;98:461–466
  55. Mao P, Zhu Z, Wang H, et al. Sustained and stable hematopoietic donor-recipient mixed chimerism after unrelated cord blood transplantation for adult patients with severe aplastic anemia. Eur J Haematol. 2005;75:430–435
  56. Ohga S, Ichino K, Goto K, et al. Unrelated donor cord blood transplantation for childhood severe aplastic anemia after a modified conditioning. Pediatr Transplant. 2006;10:497–500
  57. Motwani J, Lawson SE, Darbyshire PJ. Successful HSCT using nonradiotherapy-based conditioning regimens and alternative donors in patients with Fanconi anaemia—experience in a single UK centre. Bone Marrow Transplant. 2005;36:405–410
  58. Vibhakar R, Radhi M, Rumelhart S, Tatman D, Goldman F. Successful unrelated umbilical cord blood transplantation in children with Shwachman-Diamond syndrome. Bone Marrow Transplant. 2005;36:855–861
  59. Anasetti C, Doney KC, Storb R, et al. Marrow transplantation for severe aplastic anemia (Long-term outcome in fifty “untransfused” patients). Ann Intern Med. 1986;104:461–466
  60. Kiem HP, McDonald GB, Myerson D, et al. Marrow transplantation for hepatitis-associated aplastic anemia: a follow-up of long-term survivors. Biol Blood Marrow Transplant. 1996;2:93–99
  61. Eapen M, Ramsay NK, Mertens AC, Robison LL, DeFor T, Davies SM. Late outcomes after bone marrow transplant for aplastic anaemia. Br J Haematol. 2000;111:754–760
  62. Camitta BM, Thomas ED, Nathan DG, et al. A prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia. Blood. 1979;53:504–514
  63. Gluckman E, Socie G, Devergie A, Bourdeau-Esperou H, Traineau R, Cosset JM. Bone marrow transplantation in 107 patients with severe aplastic anemia using cyclophosphamide and thoraco-abdominal irradiation for conditioning: long-term follow-up. Blood. 1991;78:2451–2455
  64. Storb R, Evans RS, Thomas ED, et al. Paroxysmal nocturnal haemoglobinuria and refractory marrow failure treated by marrow transplantation. Br J Haematol. 1973;24:743–750
  65. Hershko C, Gale RP, Ho WG, Cline MJ. Cure of aplastic anaemia in paroxysmal nocturnal haemoglobinuria by marrow transfusion from identical twin: failure of peripheral-leucocyte transfusion to correct marrow aplasia. Lancet. 1979;1:945–947
  66. Szer J, Deeg HJ, Witherspoon RP, et al. Long-term survival after marrow transplantation for paroxysmal nocturnal hemoglobinuria with aplastic anemia. Ann Intern Med. 1984;101:193–195
  67. Antin JH, Ginsburg D, Smith BR, Nathan DG, Orkin SH, Rappeport JM. Bone marrow transplantation for paroxysmal nocturnal hemoglobinuria: eradication of the PNH clone and documentation of complete lymphohematopoietic engraftment. Blood. 1985;66:1247–1250
  68. Hegenbart U, Niederwieser D, Forman S, et al. Hematopoietic cell transplantation from related and unrelated donors after minimal conditioning as a curative treatment modality for severe paroxysmal nocturnal hemoglobinuria. Biol Blood Marrow Transplant. 2003;9:689–697
  69. Gluckman E. Current status of bone marrow transplantation for severe aplastic anemia: a preliminary report from the International Bone Marrow Transplant Registry. Transplant Proc. 1987;19:2597–2599
  70. Stern M, Passweg JR, Locasciulli A, et al. Influence of donor/recipient sex matching on outcome of allogeneic hematopoietic stem cell transplantation for aplastic anemia. Transplantation. 2006;82:218–226
  71. Frickhofen N, Kaltwasser JP, Schrezenmeier H, et al. The German Aplastic Anemia Study Group Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. N Engl J Med. 1991;324:1297–1304
  72. Tisdale JF, Dunn DE, Geller N, et al. High-dose cyclophosphamide in severe aplastic anaemia: a randomised trial. Lancet. 2000;356:1554–1559
  73. Tisdale JF, Maciejewski JP, Nunez O, Rosenfeld SJ, Young NS. Late complications following treatment for severe aplastic anemia (SAA) with high-dose cyclophosphamide (Cy): follow-up of a randomized trial. Blood. 2002;100:4668–4670
  74. Rosenfeld S, Follmann D, Nunez O, Young NS. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA. 2003;289:1130–1135
  75. Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H. Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood. 2003;101:1236–1242
  76. Tichelli A, Socie G, Henry-Amar M, et al. European Group for Blood and Marrow Transplantation Severe Aplastic Anaemia Working Party Effectiveness of immunosuppressive therapy in older patients with aplastic anemia. Ann Intern Med. 1999;130:193–201
  77. Doney K, Leisenring W, Storb R, Appelbaum FR Seattle Bone Marrow Transplant Team. Primary treatment of acquired aplastic anemia: outcomes with bone marrow transplantation and immunosuppressive therapy. Ann Intern Med. 1997;126:107–115
  78. Marsh JC, Hows JM, Bryett KA, Al-Hashimi S, Fairhead SM, Gordon-Smith EC. Survival after antilymphocyte globulin therapy for aplastic anemia depends on disease severity. Blood. 1987;70:1046–1052
  79. Scheinberg P, Nunez O, Young NS. Retreatment with rabbit anti-thymocyte globulin and ciclosporin for patients with relapsed or refractory severe aplastic anaemia. Br J Haematol. 2006;133:622–627
  80. Socie G, Rosenfeld S, Frickhofen N, Gluckman E, Tichelli A. Late clonal diseases of treated aplastic anemia. Semin Hematol. 2000;37:91–101
  81. Socie G, Henry-Amar M, Bacigalupo A, et al. Malignant tumors occurring after treatment of aplastic anemia (European Bone Marrow Transplantation—Severe Aplastic Anaemia Working Party). N Engl J Med. 1993;329:1152–1157
  82. Deeg HJ, Self S, Storb R, et al. Decreased incidence of marrow graft rejection in patients with severe aplastic anemia: changing impact of risk factors. Blood. 1986;68:1363–1368
  83. Locasciulli A, Oneto R, Bacigalupo A, et al. Outcome of patients with aplastic anemia given first line transplantion or immunosuppression in the last decade: a report from European Group for Blood and Marrow Transplantation (EBMT). Blood. 2006;108:52
  84. Locasciulli A, Oneto R, Bacigalupo A, et al. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 2007;92:11–18
  85. Storb R, Prentice RL, Buckner CD, et al. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings (Beneficial effect of a protective environment). N Engl J Med. 1983;308:302–307
  86. Guardiola P, Socie G, Li X, et al. Acute graft-versus-host disease in patients with Fanconi anemia or acquired aplastic anemia undergoing bone marrow transplantation from HLA-identical sibling donors: risk factors and influence on outcome. Blood. 2004;103:73–77
  87. Gluckman E, Auerbach A, Ash RC, et al. Allogeneic bone marrow transplants for Fanconi anemia (A preliminary report from the International Bone Marrow Transplant Registry). Bone Marrow Transplant. 1992;10(Suppl 1):53–57
  88. Gluckman E, Auerbach AD, Horowitz MM, et al. Bone marrow transplantation for Fanconi anemia. Blood. 1995;86:2856–2862
  89. Giampietro PF, Verlander PC, Davis JG, Auerbach AD. Diagnosis of Fanconi anemia in patients without congenital malformations: an international Fanconi Anemia Registry Study. Am J Med Genet. 1997;68:58–61
  90. Tischkowitz MD, Hodgson SV. Fanconi anaemia. J Med Genet. 2003;40:1–10
  91. Casado JA, Callen E, Jacome A, et al. A comprehensive strategy for the subtyping of Fanconi Anemia patients: conclusions from the Spanish Fanconi Anemia research network. J Med Genet. 2006;
  92. Wagner JE, Eapen M, Macmillan ML, et al. Unrelated donor bone marrow transplantation for the treatment of Fanconi anemia. Blood. 2007;109:2256–2262
  93. Bitan M, Or R, Shapira MY, et al. Fludarabine-based reduced intensity conditioning for stem cell transplantation of Fanconi anemia patients from fully matched related and unrelated donors. Biol Blood Marrow Transplant. 2006;12:712–718
  94. Marsh JC, Ball SE, Darbyshire P, et al. Guidelines for the diagnosis and management of acquired aplastic anaemia. Br J Haematol. 2003;123:782–801
  95. Marsh J, Schrezenmeier H, Marin P, et al. Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party. Blood. 1999;93:2191–2195
  96. Hinterberger W, Rowlings PA, Hinterberger-Fischer M, et al. Results of transplanting bone marrow from genetically identical twins into patients with aplastic anemia. Ann Intern Med. 1997;126:116–122
  97. Wang H, Chuhjo T, Yasue S, Omine M, Nakao S. Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome. Blood. 2002;100:3897–3902
  98. Nakao S, Sugimori C, Yamazaki H. Clinical significance of a small population of paroxysmal nocturnal hemoglobinuria-type cells in the management of bone marrow failure. Int J Hematol. 2006;84:118–122
  99. Passweg JR, Perez WS, Eapen M, et al. Bone marrow transplants from mismatched related and unrelated donors for severe aplastic anemia. Bone Marrow Transplant. 2006;37:641–649
  100. Kennedy-Nasser AA, Leung KS, Mahajan A, et al. Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia. Biol Blood Marrow Transplant. 2006;12:1277–1284
  101. Maury S, Balere-Appert M-L, Chir Z, et al. Unrelated allogeneic stem cell transplantation for severe acquired aplastic anemia: has outcome improved?. Blood. 2006;108:3105
  102. McGlave PB, Haake R, Miller W, Kim T, Kersey J, Ramsay NK. Therapy of severe aplastic anemia in young adults and children with allogeneic bone marrow transplantation. Blood. 1987;70:1325–1330
  103. Kim HJ, Park CY, Park YH, et al. Successful allogeneic hematopoietic stem cell transplantation using triple agent immunosuppression in severe aplastic anemia patients. Bone Marrow Transplant. 2003;31:79–86
  104. Kojima S, Hibi S, Kosaka Y, et al. Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood. 2000;96:2049–2054

PII: S1083-8791(07)00171-1

doi: 10.1016/j.bbmt.2007.02.005

Biology of Blood and Marrow Transplantation
Volume 13, Issue 5 , Pages 505-516 , May 2007

Article Tools

* Image Usage & Resolution